Isabella Ciccone, MPH

Patients with neuromyelitis optica spectrum disorder experienced poor sleep quality, indicating a significant contribution to the overall disease burden.

A recent study revealed that tandospirone citrate exhibits more positive effects in alleviating depression/anxiety and cerebellar ataxia symptoms in patients with multiple system atrophy-cerebellar subtype compared with escitalopram oxalate.

Catch up on any of the neurology news headlines you may have missed over the course of January 2024, compiled all into one place by the NeurologyLive® team.

A recent study revealed that susceptibility-based imaging can effectively differentiate pediatric-onset multiple sclerosis from pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.

An international consortium of clinicians recommended evidence-based guidelines for intracerebral hemorrhage, in which early intervention, bundled care, and time-based metrics substantially improve neurological outcomes.

Assessments on PGN-EDODM1's safety, transcript splicing correction, and clinical outcome measures data at the 5 mg/kg dose level from trial is expected this year.

Catch up on any of the neurology news headlines you may have missed over the course of December 2023, compiled all into one place by the NeurologyLive® team.

A recent study on narcolepsy type 1 and central disorders of hypersomnolence showed that patients exhibited decreased learning abilities in response to negative feedback, suggesting a link between altered decision-making and vigilance disruptions.

Take a look at the conferences in neurology that NeurologyLive® will cover for news in 2024.

Sami Khella, MD, professor of clinical neurology at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, shared his reaction to the approval of eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy.

A new study revealed daytime continuous polysomnography as a reliable and easily accessible diagnostic tool for identifying narcolepsy type 1 among pediatric patients.

With the approval, eplontersen becomes the first approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy that can be self-administered via an autoinjector.

Researchers have successfully grown norepinephrine neurons from stem cells, which are critical for regulating various bodily functions, offering new insights into neurodegenerative diseases such as Alzheimer and Parkinson.

According to a recent study, investigators found no reports of moderate or severe adverse events with a high dose of nicotinamide riboside therapy in patients with Parkinson disease.

In newly released data, AMT-130 showed a manageable safety profile at both low and high doses in patients with Huntington disease, supporting the gene therapy's continued development.

As part of our monthly clinician spotlight, NeurologyLive® highlighted headache medicine expert Amaal J. Starling, MD, FAHS, FAAN, associate professor in the department of neurology at Mayo Clinic College of Medicine.

A recent systematic practice review outlined pragmatic recommendations to enhance palliative care for patients with Parkinson disease and their caregivers, emphasizing integration, coordination, and personalized care plans.

In a recent case study of a 32-year-old man diagnosed with Friedreich ataxia, parental sample testing identified a novel intragenic deletion involving the 5'UTR upstream region and exons 1 and 2 of the FXN gene.

A new retrospective analysis revealed that modifying advanced therapies led to improved motor and subjective symptoms, emphasizing the importance of considering combination therapies when efficacy declines or adverse events arise.

A recent meta-analysis revealed significant differences in characteristic between patients with NMOSD and MS, highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.

A recent subgroup analysis of the N-MOmentum study revealed that inebilizumab had equal efficacy in reducing attacks among Asian and nonAsian patients with NMOSD, demonstrating its continued superiority over placebo.

In a recent analysis, acute levodopa induced a robust short-duration response (SDR) and long-duration response (LDR), with further improvement in the combined SDR plus LDR state in patients with Parkinson disease.

New preliminary data showed that more than 50% of dosed pediatric patients with X-linked myotubular myopathy achieved ventilator independence, with some attaining the ability to walk independently.

In a recently published study, findings revealed that mitochondrial dysfunction in patients with idiopathic REM sleep behavior disorder may serve as a predictor for the progression of Parkinson disease.

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Catch up on any of the neurology news headlines you may have missed over the course of November 2023, compiled all into one place by the NeurologyLive® team.

A recent study showed the efficacy of multicompartment diffusion measures in distinguishing patients with Friedreich ataxia from controls, emphasizing the potential for these metrics in tracking disease expression and progression.

Treated patients with hereditary ATTR-mediated amyloid polyneuropathy in the NEURO-TTRansform trial showed significantly lowered serum transthyretin concentrations, less neuropathy impairments, and better quality of life.

A recent 6-month cohort study presented at the 2023 AES Annual Meeting demonstrated that adjuvant cenobamate significantly reduced seizures in patients with severe refractory focal epilepsy and suggested potential benefits in hospitalization rates.

In a recent post hoc analysis of the Study C021 trial, findings support the idea that early adjustments to concomitant antiseizure medications enhance the retention of cenobamate, an FDA-approved treatment for focal seizures.